Imaging Endpoints (IE), a leading innovator in oncology clinical trial imaging, has unveiled its groundbreaking AIRC System—an AI-driven platform designed to transform how imaging criteria are applied and optimized in cancer drug trials.
Renowned for its advanced, customized approach to image acquisition and analysis, IE has contributed to a remarkable 95% marketing approval success rate across more than 200 regulatory approvals supported.
The AIRC System tackles long-standing challenges in trial imaging design by assimilating diverse data sources to generate tailored modifications and clarifications to standard oncology criteria, while ensuring full alignment with current regulatory requirements from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other global agencies.
Dynamic Customization: Integrates industry standards, published oncology criteria, IE’s extensive library of analysis customizations, and trial-specific information (such as experimental drug mechanism) to generate dynamic IRC (Independent Review Committee) documents.
Criteria Optimization: Offers the industry’s largest dataset and most advanced methodology for identifying criteria clarifications or modifications to optimize imaging acquisition and analysis for each unique trial.
Enhanced Regulatory Compliance: Incorporates evolving regulatory guidelines, standards, and recent findings to ensure strict adherence while simplifying and streamlining sponsor and agency review processes.
Increased Efficiency: Uses AI to compile and integrate relevant data for IE’s physician, scientific, operations, and regulatory experts to evaluate, enabling faster trial setup and more reliable outcomes.
“For over fifteen years, IE has been at the forefront of imaging CRO services within oncology. The filing of this patent marks another milestone in our commitment to Connect Imaging to the Cure™. This AI enhanced IRC System enhances the efficiency and effectiveness of oncology trials while further solidifying our industry leadership.”
— Doug Dean Burkett, CEO and President, Imaging Endpoints